Our third generation AI solution for DBT may afford physicians the ability to interpret an increasing amount of data in DBT cases and analyze each image to detect malignant lesions more efficiently and with even greater precision. “This solution is easy to integrate and implement, and it’s the ideal choice for those seeking to accurately automate density assessment and harmonize the patient experience.“The FDA Clearance of ProFound AI Version 3.0 is yet another milestone that positions iCAD and our technology as vanguards in the cancer detection realm. “With PowerLook Density Assessment software, clinicians can feel confident in their patients’ density assessment,” Hicks adds. This inconsistent reporting causes confusion, impacts patient care and derails referring physician and patient confidence,” says Randy Hicks, MD, co-owner and CEO of Regional Medical Imaging in Michigan. “Radiologist visual density assessment has suboptimal intra- and inter- observer agreement due to its visual, subjective assessment.
This software identifies the patient’s anatomy, segments the breast, and then measures adipose and fibroglandular tissue and its dispersion to determine the density category in alignment with BI-RADS 5th Edition lexicon. ICAD also launched the latest version of PowerLook ® Density Assessment software on the new PowerLook 10 platform. These tumors are often diagnosed at a later stage than cancers detected by screening and are associated with an increased risk of breast cancer-specific mortality, compared with cancers detected by screening. Many of these cancers are diagnosed as interval breast cancers, defined as those that emerge after a normal mammogram but before the woman’s next scheduled screening. Regular, age-based mammography screening reduces breast cancer mortality by approximately 20%, but screening mammography can still miss 20%-40% of breast cancers.
Results include the woman’s absolute breast cancer risk score and breast cancer risk category (low, general, moderate, and high). Moreover, ProFound AI Risk utilizes breast complexity findings, automated breast density, and age in order to calculate a woman’s short-term, absolute risk of breast cancer. The latest generation of ProFound AI Risk offers the potential to address these racial disparities and improve outcomes for women, including those who may have higher risks of developing cancers between screenings due to genetic predispositions.” “Studies show African American women have an approximately 40% higher risk of dying from breast cancer, and they are disproportionately affected by more aggressive subtypes, such as triple-negative breast cancer and inflammatory breast cancer, compared to white women. “Factoring in a woman’s racial and ethnic background adds another dimension of personalization that allows clinicians to stratify risk in a more inclusive way,” adds Stevens.